1. Japan Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Renascience Inc.

Renascience Inc.

4889.T
Renascience Inc.JP flagTokyo Stock Exchange
1,446.00
JPY
-79.00
- -
19.92BMarket Cap
Renascience Inc.
4889.T
(Tokyo Stock Exchange)

Recent

price

1,446.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
2024
2025
2026
TTM
FRC
5.87
21.37
12.23
7.91
15.27
10.44
- -
5.77
Revenue per Share
-15
-10.19
-22.33
-26.42
-20.32
8.92
- -
-12.82
Basic EPS, GAAP
-14.53
-9.19
-20.34
-22.57
-18.26
-13.94
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.69
-1.02
59.92
27.27
6.95
15.87
- -
1.21
Book Value per Share
49.42
55.84
193.24
146.71
126.4
135.32
- -
120.66
Tangible Book Value per Share
12
10
11
13
13
13
- -
13
Basic Weighted Avg Shares
72
210
139
101
194
133
69
73
Sales/Revenue/Turnover
-254.3
-41.05
-151.32
-332.06
-129.96
-134.77
-520.59
-214.71
Operating Margin (%)
3
3
3
1
2
- -
- -
- -
Depreciation Expense
-184
-100
-254
-336
-258
113
-301
-163
Net Income, GAAP
- -
- -
- -
- -
- -
21.1
- -
- -
Effective Tax Rate (%)
-255.64
-47.69
-182.51
-333.98
-133.05
85.48
-439.47
-222.11
Profit Margin (%)
977
1,013
2,390
2,167
1,960
1,720
3,323
1,899
Working Capital
380
476
199
310
356
- -
- -
366
LT Debt
622
562
2,201
1,865
1,607
1,720
3,323
1,534
Total Equity
- -
- -
- -
- -
- -
-7.56
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
35.11
- -
- -
Return on Capital (%)
- -
- -
- -
-65.26
-118.78
78.2
-57.5
-122.24
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
- -
- -
- -
LT Borrowings
356
- -
366
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
- -
13
Market Capitalization
4,843
4,347
4,309

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
2,086
- -
1,957
Cash, Cash Equivalents & STI
2,027
- -
1,906
Accounts Receivable, Net
4
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
126
- -
58
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
72.61%
93.16%
Free Cash Flow
- -
40.43%
64.45%
Net Income, GAAP
- -
-69.28%
-365.61%
Sales/Revenue/Turnover
- -
-9.66%
-48.34%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
93
27
- -
73
194
2025
- -
- -
- -
- -
133
2026
- -
- -
- -
- -
69

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
- -
- -
- -
-20.32
2025
- -
- -
- -
- -
8.92
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
GenSight Biologics S.A. (GSGTF)
Renascience Inc. (4889.T)
Poseida Therapeutics, Inc. (PSTX)
LianBio (LIANY)
PhoenixBio Co., Ltd. (6190.T)
Quince Therapeutics, Inc. (QNCX)
Business
Renascience Inc. (4889.T) develops and commercializes pharmaceuticals and medical devices targeting non-communicable aging-related diseases including cancer, diabetes, respiratory diseases and cardiovascular diseases, as well as women's and children's health conditions; its pipeline features RS5614 (TM-5614), a PAI-1 inhibitor in Phase 3 trials for chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angiosarcoma, interstitial lung disease associated with systemic scleroderma and FGF23-related hypophosphatemic rickets; RS5441, a PAI-1 inhibitor in Phase 1 for dermatological diseases; RS8001 (pyridoxamine), a water-soluble vitamin in Phase 2 for premenstrual syndrome, premenstrual dysphoric mood disorder, autism spectrum disorder and menopausal disorder; RS9001, an approved disposable ultrafine endoscope; and artificial intelligence-based solutions for diabetes treatment, maintenance hemodialysis and diagnostics. Founded in 2000 and headquartered in Sendai City, Miyagi Prefecture, Japan, following its October 2024 relocation from Tokyo, the company operates primarily in Japan through open innovation labs such as TREx at Tohoku University and HiREx at Hiroshima University. Recent developments include regulatory designation of its malignant melanoma drug as a rare disease treatment in September 2024; a joint development agreement with Taipei Medical University (TMU)-Biotech Co., Ltd. in November 2024; an agreement in January 2025 to host Northwestern University's Potocsnak Longevity Institute at TREx; initiation of Phase 3 trials for RS5614 in malignant melanoma in February 2025; and selection as a Top 40 winner in the XPRIZE Healthspan competition in May 2025.